Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Shares Issued (2016 - 2025)

Cardiff Oncology's Shares Issued history spans 14 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Shares Issued fell 96.12% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $2.1 million, down 96.09%, while the annual FY2025 figure was $2.1 million, 96.09% down from the prior year.
  • Shares Issued for Q4 2025 was $2.1 million at Cardiff Oncology, up from $25000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $53.0 million in Q4 2024 and bottomed at -$1.4 million in Q3 2024.
  • The 4-year median for Shares Issued is $107000.0 (2024), against an average of $6.3 million.
  • The largest YoY upside for Shares Issued was 101.73% in 2025 against a maximum downside of 97.2% in 2025.
  • A 4-year view of Shares Issued shows it stood at $1.3 million in 2021, then crashed by 94.06% to $75000.0 in 2022, then soared by 70629.33% to $53.0 million in 2024, then plummeted by 96.12% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Shares Issued are $2.1 million (Q4 2025), $25000.0 (Q3 2025), and $3000.0 (Q1 2025).